TRUSOPT Eye drops, solution (2023)
Βιβλιογραφική αναφορά
Για την προβολή της πλήρους καταχώρησης απαιτείται συνδρομή σε ισχύ.
Αποκτήστε πρόσβαση σε όλες τις πληροφορίες και τα εργαλεία του Galinos.gr δωρεάν για έναν μήνα απλά κάνοντας εγγραφή.
Δωρεάν εγγραφή
Αποκτήστε πρόσβαση σε όλες τις πληροφορίες και τα εργαλεία του Galinos.gr δωρεάν για έναν μήνα απλά κάνοντας εγγραφή.
Δωρεάν εγγραφή
Περιεχόμενα
Name of the medicinal product
TRUSOPT 20 mg/ml eye drops, solution.
Qualitative and quantitative composition
Each ml contains 22.26 mg of dorzolamide hydrochloride equivalent to 20 mg of dorzolamide. <u>Excipient with known effect:</u> One ml of eye drops solution contains 0.075 mg benzalkonium chloride and one ...
Pharmaceutical form
Eye drops, solution. Clear, colourless to nearly colourless, slightly viscous, solution.
Therapeutic indications
TRUSOPT is indicated: as adjunctive therapy to beta-blockers, as monotherapy in patients unresponsive to beta-blockers or in whom beta-blockers are contraindicated, in the treatment of elevated intra-ocular ...
Posology and method of administration
Posology When used as monotherapy, the dose is one drop of dorzolamide in the conjunctival sac of the affected eye(s), three times daily. When used as adjunctive therapy with an ophthalmic beta-blocker, ...
Contraindications
Hypersensitivity to the active substance or to any of the excipients listed in section 6.1. Dorzolamide has not been studied in patients with severe renal impairment (CrCl <30 ml/min) or with hyperchloraemic ...
Special warnings and precautions for use
Dorzolamide has not been studied in patients with hepatic impairment and should therefore be used with caution in such patients. The management of patients with acute angle-closure glaucoma requires therapeutic ...
Interaction with other medicinal products and other forms of interaction
Specific drug interaction studies have not been performed with dorzolamide. In clinical studies, dorzolamide was used concomitantly with the following medications without evidence of adverse interactions: ...
Fertility, pregnancy and lactation
Pregnancy Dorzolamide should not be used during pregnancy. There are no or limited amount of data from the use of dorzolamide in pregnant women. In rabbits, dorzolamide produced teratogenic effects at ...
Effects on ability to drive and use machines
No studies on the effects on the ability to drive and use machines have been performed. Possible side effects such as dizziness and visual disturbances may affect the ability to drive and use machines. ...
Undesirable effects
TRUSOPT was evaluated in more than 1400 individuals in controlled and uncontrolled clinical studies. In long-term studies of 1108 patients treated with TRUSOPT as monotherapy or as adjunctive therapy with ...
Overdose
Only limited information is available with regard to human overdose by accidental or deliberate ingestion of dorzolamide hydrochloride. Symptoms The following have been reported with oral ingestion: somnolence; ...
Pharmacodynamic properties
Pharmacotherapeutic group: Antiglaucoma preparations and miotics, Carbonic Anhydrase Inhibitors, dorzolamide ATC code: S01EC03 Mechanism of Action Carbonic anhydrase (CA) is an enzyme found in many tissues ...
Pharmacokinetic properties
Unlike oral carbonic anhydrase inhibitors, topical administration of dorzolamide hydrochloride allows for the active substance to exert its effects directly in the eye at substantially lower doses and ...
Preclinical safety data
The main findings in animal studies with dorzolamide hydrochloride administered orally were related to the pharmacological effects of systemic carbonic anhydrase inhibition. Some of these findings were ...
List of excipients
Benzalkonium chloride Hydroxyethylcellulose Mannitol (E421) Sodium citrate (E331) Sodium hydroxide (E524) for pH adjustment Water for injections
Incompatibilities
Not Applicable.
Shelf life
3 years. After first opening the container, TRUSOPT should be used no longer than 28 days.
Special precautions for storage
Store container in original carton in order to protect from light. This medicinal product does not require any special temperature storage conditions. For storage conditions after first opening of the ...
Nature and contents of container
TRUSOPT container contains 5 ml of solution. Two alternate containers may be marketed. White translucent low-density polyethylene (LDPE) container with a transparent linear LDPE dropper tip and a white ...
Special precautions for disposal and other handling
No special requirements.
Marketing authorization holder
Santen Oy, Niittyhaankatu 20, 33720, Tampere, Finland
Marketing authorization number(s)
PL 16058/0014
Date of first authorization / renewal of the authorization
Date of first authorisation: 09 January 1995 Date of latest renewal: 11 November 2009
Date of revision of the text
26 January 2023
Πηγαίο έγγραφο
Το πηγαίο έγγραφο για αυτήν την βιβλιογραφική αναφορά είναι διαθέσιμο προς μεταφόρτωση:
